Disappointing Drug Trials Drag on Biotech ETFs
January 21, 2016 at 17:00 PM EST
Biotechnology stocks and sector-related exchange traded funds rallied late Wednesday but could not maintain their momentum after a high profile drug trial failure. Alkermes (NasdaqGS: ALKS), a central nervous-system drug developer, revealed two late-stage Phase 3 studies of its treatment for...